Expression of the cystic fibrosis transmembrane conductance regulator gene in the respiratory tract of normal individuals and individuals with cystic fibrosis - PubMed (original) (raw)

Expression of the cystic fibrosis transmembrane conductance regulator gene in the respiratory tract of normal individuals and individuals with cystic fibrosis

B C Trapnell et al. Proc Natl Acad Sci U S A. 1991.

Abstract

The most common mutation of the cystic fibrosis transmembrane conductance regulator gene, CFTR, associated with the clinical disorder cystic fibrosis (CF) is called "delta Phe508," a triple-base deletion resulting in loss of phenylalanine at residue 508 of the predicted 1480-amino acid CFTR protein. In the context that the lung is the major site of morbidity and mortality in CF, we evaluated airway epithelial cells for CFTR mRNA transcripts in normal individuals, normal-delta Phe508 heterozygotes, and delta Phe508 homozygotes to determine if the normal and delta Phe508 CFTR alleles are expressed in the respiratory epithelium, to what extent they are expressed, and whether there are relative differences in the expression of the normal and abnormal alleles at the mRNA level. Respiratory tract epithelial cells recovered by fiberoptic bronchoscopy with a cytology brush demonstrated CFTR mRNA transcripts with sequences appropriately reflecting the normal and delta Phe508 CFTR alleles of the various study groups. CFTR gene expression quantified by limited polymerase chain reaction amplification showed that in normal individuals, CFTR mRNA transcripts are expressed in nasal, tracheal, and bronchial epithelial cells at approximately 1-2 copies per cell, more than 100-fold greater than in pharyngeal epithelium. Importantly, allele-specific hybridization studies demonstrated that the normal and delta Phe508 CFTR alleles are expressed in the respiratory epithelium in similar amounts.

PubMed Disclaimer

Cited by

Limitations of cell culture of airway epithelium collected by a nasal brushing technique.
Hull J, Harris A. Hull J, et al. In Vitro Cell Dev Biol Anim. 1994 Aug;30(8):488-9. doi: 10.1007/BF02631320. In Vitro Cell Dev Biol Anim. 1994. PMID: 27519862 No abstract available.
In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.
Sermet-Gaudelus I, Renouil M, Fajac A, Bidou L, Parbaille B, Pierrot S, Davy N, Bismuth E, Reinert P, Lenoir G, Lesure JF, Rousset JP, Edelman A. Sermet-Gaudelus I, et al. BMC Med. 2007 Mar 29;5:5. doi: 10.1186/1741-7015-5-5. BMC Med. 2007. PMID: 17394637 Free PMC article. Clinical Trial.
Treatment of human disease by adeno-associated viral gene transfer.
Warrington KH Jr, Herzog RW. Warrington KH Jr, et al. Hum Genet. 2006 Jul;119(6):571-603. doi: 10.1007/s00439-006-0165-6. Epub 2006 Apr 13. Hum Genet. 2006. PMID: 16612615 Review.
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes.
Baldassarri M, Zguro K, Tomati V, Pastorino C, Fava F, Croci S, Bruttini M, Picchiotti N, Furini S, Pedemonte N, Gabbi C, Renieri A, Fallerini C; Gen-Covid Multicenter Study. Baldassarri M, et al. Cells. 2022 Dec 16;11(24):4096. doi: 10.3390/cells11244096. Cells. 2022. PMID: 36552859 Free PMC article.
Characterization of wild-type and deltaF508 cystic fibrosis transmembrane regulator in human respiratory epithelia.
Kreda SM, Mall M, Mengos A, Rochelle L, Yankaskas J, Riordan JR, Boucher RC. Kreda SM, et al. Mol Biol Cell. 2005 May;16(5):2154-67. doi: 10.1091/mbc.e04-11-1010. Epub 2005 Feb 16. Mol Biol Cell. 2005. PMID: 15716351 Free PMC article.

References

1. Nature. 1990 Sep 27;347(6291):382-6 - PubMed
1. Biochemistry. 1983 May 10;22(10):2365-72 - PubMed
1. Proc Natl Acad Sci U S A. 1988 Oct;85(20):7652-6 - PubMed
1. Proc Natl Acad Sci U S A. 1989 Dec;86(24):9717-21 - PubMed
1. Science. 1988 Jan 29;239(4839):487-91 - PubMed

Expression of the cystic fibrosis transmembrane conductance regulator gene in the respiratory tract of normal individuals and individuals with cystic fibrosis - PubMed (original) (raw)